What are the main functions and effects of filgotinib?

Filgotinib (Filgotinib) is an oral, small-molecule JAK1 selective inhibitor. It is a targeted immunomodulatory drug. It is mainly used to treat autoimmune diseases, especially in chronic inflammatory diseases such as rheumatoid arthritis (RA). It has significant efficacy. Its mechanism of action is mainly by blocking the JAK1 kinase activity in the JAK-STAT signaling pathway, thereby intervening in the signaling of pro-inflammatory cytokines, reducing abnormal activation of the immune system, slowing down disease progression and improving symptoms.

In clinical application, the main indication of filgotinib is moderately to severely active rheumatoid arthritis, especially in patients who have an inadequate response to or intolerance to one or more traditional disease-modifying antirheumatic drugs (such as methotrexate). Compared with other broad-spectrum JAK inhibitors, filgotinib has higher selectivity for JAK1. While reducing inflammatory signals, it less affects other pathways related to hematopoiesis and lipid metabolism. Therefore, the side effects are more controllable and the safety of long-term medication is relatively better.

In addition, filgotinib also shows potential therapeutic prospects in other autoimmune diseases such as ulcerative colitis, Crohn's disease, psoriatic arthritis, etc. Multiple clinical trials are ongoing, some of which have entered Phase III, and its scope of indications may be expanded in the future.

It is worth noting that the efficacy of filgotinib is not only reflected in the reduction of inflammatory factor levels, but also in the reduction of joint pain, shortened morning stiffness, and improved quality of life in patients. Because of its rapid onset of action, some patients experience relief from joint swelling and stiffness within weeks of taking it, making it a popular oral treatment option.

As a targeted drug, filgotinib also requires individualized evaluation, including liver and kidney function, infection risk and other factors. Due to its immunosuppressive properties, some patients may be more susceptible to herpes zoster or upper respiratory tract infection during use. Therefore, regular monitoring is required during use and the guidance of a doctor must be followed.

Reference materials:https://go.drugbank.com/drugs/DB14845